Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcitonin salmon is a synthetic or recombinant form of the peptide hormone found in the thyroid gland of fish, particularly salmon. It is a 32-amino acid polypeptide that acts as an agonist at the human calcitonin receptor. Its primary mechanism is to inhibit osteoclast-mediated bone resorption, thereby reducing bone turnover and lowering serum calcium levels. This makes it effective for treating postmenopausal osteoporosis, Paget’s disease of bone (especially in patients unresponsive or intolerant to other therapies), and hypercalcemia. Calcitonin salmon can be administered via nasal spray or injection and has greater potency and longer duration than mammalian forms of the hormone[1][2][3][4][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcitonin salmon.